News

Video

Understanding Efficacy, Safety, and PSA Kinetics of Apalutamide Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Author(s):

Neal D. Shore, MD, FACS

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

This content is not certified for continuing education. The speaker has been compensated by Janssen Biotech, Inc.

Related Videos
Anthony V. D'Amico, MD, PhD
Ruben Olivares, MD
Ruben Olivares, MD
Carmen Guerra, MD, MSCE, FACP
Jeffrey P. Townsend, PhD
Robert Dreicer, MD
Alicia Morgans, MD, MPH
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Praful K. Ravi, MB, BChir, MRCP
Josep Maria Piulats Rodriguez, MD, PhD
Related Content
The OncFive: Top Oncology Articles for the Week of 9/1
September 7th 2024

The OncFive: Top Oncology Articles for the Week of 9/1

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
August 29th 2024

ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Prostate Cancer
August 22nd 2024

Olaparib Monotherapy Elicits Responses in HRR+ Prostate Cancer With High-Risk Biochemical Recurrence

Kara N. Maxwell, MD, PhD, director, Men and BRCA Program, Basser Center, associate professor, medicine (hematology-oncology), Perelman School of Medicine, University of Pennsylvania
August 20th 2024

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers